Literature DB >> 6232275

Effect of modification of sialic acid on enzymic hydrolysis of gangliosides GM1 and GM2.

S C Li, S Serizawa, Y T Li, K Nakamura, S Handa.   

Abstract

In order to understand the mechanism of action of the activator proteins for the enzymic hydrolysis of GM1 (GM1-activator; Li, S.-C. and Li, Y.-T. (1976) J. Biol. Chem. 251, 1159-1163; for ganglioside designations, see Svennerholm, L. (1963) J. Neurochem. 10, 613) and GM2 (GM2-activator; Li, S.-C., Hirabayashi, Y., and Li, Y.-T. (1981) J. Biol. Chem. 256, 6234-6240), we have studied the effect of chemical modifications of GM1 and GM2 on their susceptibility to the activator-assisted enzymic hydrolysis. Chemically modified GM1 and GM2 were prepared by methyl esterification (Me-GM1 or Me-GM2) and reduction (HO-GM1 or HO-GM2) of the -COO- group of the sialic acid. Me-GM1 and HO-GM1 could be hydrolyzed by human hepatic beta-galactosidase in the presence of GM1-activator at rates comparable to that of the native GM1. However, in contrast to native GM2, Me-GM2 and HO-GM2 were resistant to the hydrolysis by human hepatic beta-hexosaminidase A in the presence of GM2-activator. When GM2-activator was replaced by sodium taurodeoxycholate, the native GM2 and both modified GM2 could be hydrolyzed by beta-hexosaminidase A. These results suggest that the carboxyl function of sialic acid in GM1 is not vital for beta-galactosidase or GM1-activator to carry out the cleavage of the terminal Gal. In the case of GM2 hydrolysis, the carboxyl function of sialic acid is involved in the interaction with GM2-activator. Our results also indicate that the mode of action of GM1-activator is different from that of GM2-activator and that the action of GM2-activator is different from that of sodium taurodeoxycholate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6232275

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Recombinant GM2-activator protein stimulates in vivo degradation of GA2 in GM2 gangliosidosis AB variant fibroblasts but exhibits no detectable binding of GA2 in an in vitro assay.

Authors:  U Bierfreund; T Lemm; A Hoffmann; G Uhlhorn-Dierks; R A Childs; C T Yuen; T Feizi; K Sandhoff
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

2.  Effect of structural modifications of ganglioside GM2 on intra-molecular carbohydrate-to-carbohydrate interaction and enzymatic susceptibility.

Authors:  Yu-Teh Li; Su-Chen Li; Makoto Kiso; Hideharu Ishida; Laura Mauri; Laura Raimondi; Anna Bernardi; Sandro Sonnino
Journal:  Biochim Biophys Acta       Date:  2007-10-05

3.  Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta.

Authors:  Hiromi Akeboshi; Yasunori Chiba; Yoshiko Kasahara; Minako Takashiba; Yuki Takaoka; Mai Ohsawa; Youichi Tajima; Ikuo Kawashima; Daisuke Tsuji; Kohji Itoh; Hitoshi Sakuraba; Yoshifumi Jigami
Journal:  Appl Environ Microbiol       Date:  2007-06-08       Impact factor: 4.792

4.  A triple-binding-domain model explains the specificity of the interaction of a sphingolipid activator protein (SAP-1) with sulphatide, GM1-ganglioside and globotriaosylceramide.

Authors:  C H Wynn
Journal:  Biochem J       Date:  1986-12-15       Impact factor: 3.857

5.  Isolation and characterization of an activator protein for the hydrolysis of ganglioside GM2 from the roe of striped mullet (Mugil cephalus).

Authors:  R DeGasperi; Y T Li; S C Li
Journal:  Biochem J       Date:  1989-06-15       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.